Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan 1;75(1):58-64.
doi: 10.1001/jamaneurol.2017.3339.

Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis

Jinsy A Andrews  1   2 , Lisa Meng  1 , Sarah F Kulke  1 , Stacy A Rudnicki  1 , Andrew A Wolff  1 , Michael E Bozik  3 , Fady I Malik  1 , Jeremy M Shefner  4
Affiliations
Clinical Trial

Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis

Jinsy A Andrews et al. JAMA Neurol. .

Abstract

Importance: The prognostic value of slow vital capacity (SVC) in relation to respiratory function decline and disease progression in patients with amyotrophic lateral sclerosis (ALS) is not well understood.

Objective: To investigate the rate of decline in percentage predicted SVC and its association with respiratory-related clinical events and mortality in patients with ALS.

Design, setting, and participants: This retrospective study included 893 placebo-treated patients from 2 large clinical trials (EMPOWER and BENEFIT-ALS, conducted from March 28, 2011, to November 1, 2012, and from October 23, 2012, to March 21, 2014, respectively) and an ALS trial database (PRO-ACT, containing studies completed between 1990 and 2010) to investigate the rate of decline in SVC. Data from the EMPOWER trial (which enrolled adults with possible, probable, or definite ALS; symptom onset within 24 months before screening; and upright SVC at least 65% of predicted value for age, height, and sex) were used to assess the relationship of SVC to respiratory-related clinical events; 456 patients randomized to placebo were used in this analysis. The 2 clinical trials included patients from North America, Australia, and Europe.

Main outcomes and measures: Clinical events included the earlier of time to death or time to decline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) respiratory subdomain, time to onset of respiratory insufficiency, time to tracheostomy, and all-cause mortality.

Results: Among 893 placebo-treated patients with ALS, the mean (SD) patient age was 56.7 (11.2) years, and the mean (SD) SVC was 90.5% (17.1%) at baseline; 65.5% (585 of 893) were male, and 20.5% (183 of 893) had bulbar-onset ALS. In EMPOWER, average decline of SVC from baseline through 1.5-year follow-up was -2.7 percentage points per month. Steeper declines were found in patients older than 65 years (-3.6 percentage points per month [P = .005 vs <50 years and P = .007 vs 50-65 years) and in patients with an ALSFRS-R total score of 39 or less at baseline (-3.1 percentage points per month [P < .001 vs >39]). When the rate of decline of SVC was slower by 1.5 percentage points per month in the first 6 months, risk reductions for events after 6 months were 19% for decline in the ALSFRS-R respiratory subdomain or death after 6 months, 22% for first onset of respiratory insufficiency or death after 6 months, 23% for first occurrence of tracheostomy or death after 6 months, and 23% for death at any time after 6 months (P < .001 for all).

Conclusions and relevance: The rate of decline in SVC is associated with meaningful clinical events in ALS, including respiratory failure, tracheostomy, or death, suggesting that it is an important indicator of clinical progression.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Meng, Kulke, Rudnicki, Wolff, and Malik reported being shareholders of Cytokinetics, Inc. Dr Shefner reported being a consultant to Biogen, Cytokinetics, Inc, and Neuraltus Pharmaceuticals, Inc and reported receiving grant funding from The ALS Association, Muscular Dystrophy Association, and ALS Finding a Cure.

Figures

Figure 1.
Figure 1.. Rates of Decline in Slow Vital Capacity (SVC) Among Data Sets From Large Clinical Trials
Data from EMPOWER and BENEFIT-ALS are from the placebo groups. All groups are described in the introduction.
Figure 2.
Figure 2.. Probability of Respiratory Failure–Free Survival Related to the Rate of Decline of Slow Vital Capacity
Data are based on a Cox proportional hazards regression model of time to clinical events. The 3 percentages are slope of change in percent predicted slow vital capacity per month.
See this image and copyright information in PMC

References

    1. Chiò A, Logroscino G, Hardiman O, et al. ; Eurals Consortium . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6):310-323. - PMC - PubMed
    1. Marin B, Logroscino G, Boumédiene F, et al. . Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur J Epidemiol. 2016;31(3):229-245. - PubMed
    1. National Institute of Neurological Disorders and Stroke Amyotrophic lateral sclerosis (ALS) fact sheet. http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_AL.... Accessed April 10, 2016.
    1. Laszlo G. Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax. 2006;61(9):744-746. - PMC - PubMed
    1. Naureckas ET, Solway J. Disturbances of respiratory function In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 19th ed. New York, NY: McGraw-Hill; 2015:chap 306e.

Publication types